FMC Corporation 2025 Q2 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2025. FMC Corporation is a global agricultural sciences company operating in a single segment, developing crop protection chemicals (insecticides, herbicides, fungicides) and plant health products. The company recently completed the sale of its Global Specialty Solutions (GSS) business and announced a plan to divest its commercial business in India, which will be classified as held for sale starting in Q3 2025.
Key Financial Metrics
| Metric (in Millions) | Q2 2025 | Q2 2024 | YTD 2025 | YTD 2024 |
|---|---|---|---|---|
| Revenue | $1,050.5 | $1,038.4 | $1,841.9 | $1,956.4 |
| Gross Margin | $406.3 | $398.1 | $723.0 | $737.8 |
| Gross Margin % | 38.7% | 38.3% | 39.2% | 37.7% |
| Net Income (GAAP) | $67.8 | $295.2 | $52.2 | $292.1 |
| Net Income Attributable to FMC | $66.7 | $295.1 | $51.2 | $292.4 |
| Diluted EPS (GAAP) | $0.53 | $2.35 | $0.41 | $2.33 |
| Adjusted EBITDA (Non-GAAP) | $206.5 | $201.7 | $326.2 | $362.3 |
| Operating Cash Flow (Continuing Ops) | — | — | $(479.1) | $149.3 |
| Free Cash Flow (Non-GAAP) | — | — | $(556.0) | $92.6 |
| Total Debt | $4,163.3 | — | $4,163.3 | — |
| Cash and Equivalents | $438.2 | — | $438.2 | — |
Material Changes vs. Prior Period
- Revenue: Q2 revenue increased 1% year-over-year (YoY) driven by 6% volume growth, partially offset by a 3% price decline (largely due to cost-plus contract adjustments) and a 1% foreign currency headwind. YTD revenue decreased 6% due to pricing declines and currency impacts.
- Profitability: GAAP Net Income dropped significantly ($228.4M decrease in Q2) primarily due to the absence of a ~$300M discrete tax benefit recorded in Q2 2024 related to a Swiss technology center. Adjusted after-tax earnings from continuing operations increased 10% YoY to $86.7M.
- Expenses: SG&A expenses increased 7% YoY due to investments in new products and sales force expansion in Brazil. R&D expenses decreased 13% YoY due to project timing and cost reduction efforts. Restructuring charges decreased significantly to $36.7M in Q2 2025 from $95.1M in Q2 2024.
- Cash Flow: Operating cash flow for continuing operations turned negative ($479.1M outflow) YTD 2025 compared to a $149.3M inflow in 2024. This was driven by a $453.8M decrease in advance payments from customers, a $165.5M increase in inventory, and higher trade receivables.
- Debt: Total debt increased to $4.16B from $3.37B at year-end 2024. The company issued $750M in Subordinated Notes in May 2025 and used proceeds to redeem $500M of senior notes.
Guidance, Outlook, and Risks
- 2025 Outlook:
- Revenue (ex-India): Expected to range from $4.08B to $4.28B (down 2% midpoint vs. 2024).
- Adjusted EBITDA: Expected to range from $870M to $950M (up 1% midpoint vs. 2024).
- Adjusted EPS: Expected to range from $3.26 to $3.70 (essentially flat midpoint vs. 2024).
- Free Cash Flow: Expected to range from $200M to $400M.
- Divestitures: The India commercial business is being divested; assets will be held for sale starting Q3 2025. The GSS business sale was completed in late 2024 with final asset transfers ongoing.
- Restructuring: "Project Focus" is expected to be complete by end of 2025, with total pre-tax charges estimated at $375M–$425M. Targeted annual run-rate savings exceed $225M.
- Risks & Contingencies:
- Legal: Multiple derivative lawsuits filed in 2025 alleging fiduciary duty breaches; cases are currently stayed pending motions to dismiss.
- Environmental: Total environmental reserves are $614.6M. Reasonably possible losses exceed accrued amounts by approximately $290M.
- Tax: New U.S. tax legislation ("One Big Beautiful Bill Act") enacted July 4, 2025, is being evaluated for impact. OECD guidance on Swiss tax credits may increase future top-up tax liabilities.
Investor Verification Checklist
- Working Capital Normalization: Verify the sustainability of the negative operating cash flow, specifically the timing of customer advance payments and inventory build-up in Brazil.
- India Divestiture: Monitor the progress of the India commercial business sale and the classification of assets as "held for sale" in Q3 2025.
- Debt Covenants: Confirm continued compliance with the amended leverage ratio (max 5.25x through Sept 2025) and interest coverage ratio (min 3.00x).
- Legal Reserves: Track the $34.5M reduction in legal reserves in discontinued operations and the status of pending derivative litigation.
- Price/Mix Dynamics: Assess the impact of "cost-plus" contract adjustments on diamide partners on future pricing and margins.